XY0597

XY0597 is a novel small molecule degrader, specifically a proteolysis-targeting chimera (PROTAC), that targets Cyclin-dependent kinase 9 (CDK9). CDK9 is a critical component of the positive transcription elongation factor b (P-TEFb) complex, which facilitates the transition of RNA polymerase II (RNA Pol II) from promoter-proximal pausing to productive elongation. By inducing the degradation of CDK9, XY0597 effectively inhibits the phosphorylation of RNA Pol II at Serine 2, leading to the suppression of transcription for several key oncogenic and anti-apoptotic genes, most notably MCL-1. In the context of gastroesophageal cancer (GEAC), XY0597 has demonstrated the ability to increase chromatin accessibility and downregulate the YAP/TEAD signaling pathway, which is often associated with resistance to conventional therapies like radiation. Preclinical studies indicate that XY0597 potently inhibits GEAC cell growth, invasion, and tumor sphere formation, particularly in radiation-resistant models, and shows synergistic activity when combined with YAP1/TEAD inhibitors.